Osteoporosis

Latest

USPSTF Issues Recommendation for Vitamin D, Calcium Supplementation for Fracture Prevention

USPSTF Issues Recommendation for Vitamin D, Calcium Supplementation for Fracture Prevention

The USPSTF has released recommendations for vitamin D and calcium supplementation for the primary prevention of fractures in community-dwelling adults.

Greater Bone Formation With Teriparatide vs Zoledronic Acid in Osteoporosis

Greater Bone Formation With Teriparatide vs Zoledronic Acid in Osteoporosis

Researchers have determined that treatment for osteoporosis with teriparatide is associated with greater bone formation than treatment with zoledronic acid.

Effect of Growth Hormone Treatment on BMD in Adults With Prader-Willi Syndrome

Effect of Growth Hormone Treatment on BMD in Adults With Prader-Willi Syndrome

Researchers investigated the effects of growth hormone vs placebo, as well as the effects of sex steroid replacement therapy on bone mineral density in growth hormone-treated young adults with Prader-Willi syndrome who had attained adult height.

Osteoporotic Fracture Risk Predicted by Vertebral Trabecular Attenuation on Routine CT

Osteoporotic Fracture Risk Predicted by Vertebral Trabecular Attenuation on Routine CT

Researchers showed that decreased L1 trabecular attenuation is associated with increased risk for future osteoporotic fractures in adult patients aged ≥65 years undergoing abdominopelvic CT scans for other indications.

Romosozumab Followed by Alendronate Decreases Fracture Risk in Women With Osteoporosis

Romosozumab Followed by Alendronate Decreases Fracture Risk in Women With Osteoporosis

In postmenopausal women at high risk for fracture, treatment with romosozumab for 12 months, followed by alendronate, was associated with significantly fewer hip fractures than treatment with alendronate alone.

Fracture Risk in Postmenopausal Women With Osteoporosis May Improve With Growth Hormone Therapy

Fracture Risk in Postmenopausal Women With Osteoporosis May Improve With Growth Hormone Therapy

A recent literature review and meta-analysis indicates that growth hormone therapy may reduce the risk for fracture in patients with osteoporosis.

Teriparatide More Effective Than Risedronate in Osteoporotic Fractures

Teriparatide More Effective Than Risedronate in Osteoporotic Fractures

Teriparatide is associated with a lower risk for new vertebral and clinical fractures compared with risedronate in post-menopausal women being treated for severe osteoporosis.

Prolonged Antiresorptive Activity With Zoledronate in Postmenopausal Osteopenia

Prolonged Antiresorptive Activity With Zoledronate in Postmenopausal Osteopenia

In a randomized multidose trial, single doses of zoledronate (1-5 mg) prolonged antiresorptive activity ≥3 years in postmenopausal women with osteopenia.

Risks Associated With Denosumab Discontinuation

Risks Associated With Denosumab Discontinuation

Risk of vertebral fractures may be increased with discontinuation of denosumab therapy.

USPSTF: Screening Recommendations Updated for Preventing Osteoporotic Fractures

USPSTF: Screening Recommendations Updated for Preventing Osteoporotic Fractures

The task force recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women ≥65 years and postmenopausal women.

Sign Up for Free e-Newsletters

CME Focus